316 articles in this topic
Comprehensive study of 670 brain tumor samples uncovers why immunotherapies fail and how tumors evade treatment through immune system changes.
Spatial multi-omics reveals how specific fibroblasts create immunosuppressive environments that fuel colorectal cancer spread to the liver.
Massive spatial analysis reveals conserved fibroblast subtypes that control immune infiltration and therapy response across cancer types.
New blood test identifies early-stage breast and lung cancers by measuring epigenetic chaos in cell-free DNA fragments.
Combination therapy with olaparib and irinotecan demonstrated activity in pediatric tumors, particularly those with genetic instability.
New study shows circulating tumor cells can predict treatment response and reveal drug resistance patterns.
Switching between different drug types prevents resistance in breast cancer therapy, offering hope for extended treatment options.
Large trial finds combination therapy doesn't improve survival or response rates compared to standard treatment alone.
Antibody-drug conjugate achieved 21% response rate in heavily pretreated patients with limited options.
Scientists identify TP53 and CYLD mutations that make HPV-positive head and neck cancers more aggressive and treatment-resistant.
Large study finds diabetes drug metformin only slightly slows harmful blood cell mutations, questioning its use for cancer prevention.
New study reveals combining PARP inhibitors with bevacizumab extends progression-free survival in previously treated ovarian cancer patients.
